---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061683"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:54:51.347497+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharmaceuticals extends financial statement deadline to Jul 31, 2024; revolver cut to $50M

## Summary
- Annual audited 2023 financials, restated Q2 2023, Q3 2023, and Q1 2024 statements due July 31, 2024, per Third Amendment.
- Revolving commitment permanently reduced from $100M to $50M; availability restriction superseded by permanent cut.
- Minimum liquidity covenant reduced from $50M to $10M; prior liquidity covenant waiver terminated.
- Covenant flexibility restriction continues until all financials delivered; failure to meet deadline is an event of default.
- Credit obligations secured by substantially all assets; default could lead to acceleration and foreclosure.

## SEC filing metadata
- accession: 0001104659-24-061683
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465924061683/0001104659-24-061683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465924061683/tm2414362d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061683
- JSON: https://secwatch.observer/filing/0001104659-24-061683.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061683.txt

## Key facts
- Material Agreements
  EAGLE PHARMACEUTICALS, INC. amended Third Amendment to Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto valued at permanent reduction of availability under the revolving facility under the Amended Credit Agreement (effective 2024-05-14).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto
  - Value: permanent reduction of availability under the revolving facility under the Amended Credit Agreement
  - Effective: 2024-05-14
  source text: On May 14, 2024 (the “Amendment Date”), Eagle Pharmaceuticals, Inc. (the “Company”), entered into a Third Amendment to Third Amended and Restated Credit Agreement (the “Third Amendment Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the lenders party thereto (the “Lenders”), with an effective date of May 13, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924061683/0001104659-24-061683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.